Latest Lung Cancer News

Page 4 of 4
Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.
Ada Torres
Ada Torres
5 May 2025
Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.
Ada Torres
Ada Torres
30 Apr 2025
4DMedical Limited reports a 103% surge in year-to-date revenue, secures major contracts with leading healthcare providers, and advances its CT:VQ™ technology towards FDA clearance.
Ada Torres
Ada Torres
29 Apr 2025
Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
29 Apr 2025
Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.
Ada Torres
Ada Torres
31 Jan 2025
Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
31 Jan 2025
Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.
Ada Torres
Ada Torres
30 Jan 2025